Therapeutic potentials of gene silencing by RNA interference: Principles, challenges, and new strategies

Gene

Volumn 538, Issue 2, 2014, Pages 217-227

  Deng, Yan ^a,b   Wang, Chi Chiu ^a   Choy, Kwong Wai ^a,b   Du, Quan ^c   Chen, Jiao ^a   Wang, Qin ^d   Li, Lu ^a   Chung, Tony Kwok Hung ^a   Tang, Tao ^a,b  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d LINYI PEOPLE'S HOSPITAL   (China)

Author keywords

Gene silencing; RNA interference; RNAi delivery; Therapeutics

Indexed keywords

GENE-SILENCING; RNA INTERFERENCE; RNAI DELIVERY; THERAPEUTICS;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG DELIVERY SYSTEMS; GENE SILENCING; GENETIC THERAPY; GENETIC VECTORS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; NEOPLASMS; NEURODEGENERATIVE DISEASES; RNA INTERFERENCE; RNA STABILITY; RNA, SMALL INTERFERING;

EID: 84893909299     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2013.12.019     Document Type: Review

References (130)

1. Aagaard L., Rossi J.J. RNAi therapeutics: principles, prospects and challenges. Adv. Drug Deliv. Rev. 2007, 59:75-86.
2. Akinc A., et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat. Biotechnol. 2008, 26:561-569.
3. Alexis F., Pridgen E., Molnar L.K., Farokhzad O.C. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol. Pharm. 2008, 5:505-515.
4. Allen T.M. Ligand-targeted therapeutics in anticancer therapy. Nat. Rev. Cancer 2002, 2:750-763.
5. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
6. Barton K.M., Burch B.D., Soriano-Sarabia N., Margolis D.M. Prospects for treatment of latent HIV. Clin. Pharmacol. Ther. 2012, 93:46-56.
7. Birmingham A., et al. 3' UTR seed matches, but not overall identity, are associated with RNAi off-targets. Nat. Methods 2006, 3:199-204.
8. Bora R.S., Gupta D., Mukkur T.K., Saini K.S. RNA interference therapeutics for cancer: challenges and opportunities (review). Mol. Med. Rep. 2012, 6:9-15.
9. Boudreau R.L., Monteys A.M., Davidson B.L. Minimizing variables among hairpin-based RNAi vectors reveals the potency of shRNAs. RNA 2008, 14:1834-1844.
10. Campochiaro P.A. Potential applications for RNAi to probe pathogenesis and develop new treatments for ocular disorders. Gene Ther. 2006, 13:559-562.
11. Chakraborty A.K., Pawelek J.M. GnT-V, macrophage and cancer metastasis: a common link. Clin. Exp. Metastasis 2003, 20:365-373.
12. Chang J.H., Garg N.K., Lunde E., Han K.Y., Jain S., Azar D.T. Corneal neovascularization: an anti-VEGF therapy review. Surv. Ophthalmol. 2012, 57:415-429.
13. Chaturvedi K., et al. Cyclodextrin-based siRNA delivery nanocarriers: a state-of-the-art review. Expert. Opin. Drug Deliv. 2011, 8:1455-1468.
14. Chen S.H., Zhaori G. Potential clinical applications of siRNA technique: benefits and limitations. Eur. J. Clin. Invest. 2011, 41:221-232.
15. Chen Y., Bathula S.R., Li J., Huang L. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer. J. Biol. Chem. 2010, 285:22639-22650.
16. Chong R.H., et al. Gene silencing following siRNA delivery to skin via coated steel microneedles: in vitro and in vivo proof-of-concept. J. Control. Release 2013, 166:211-219.
17. Couto L.B., High K.A. Viral vector-mediated RNA interference. Curr. Opin. Pharmacol. 2010, 10:534-542.
18. Czech M.P., Aouadi M., Tesz G.J. RNAi-based therapeutic strategies for metabolic disease. Nat. Rev. Endocrinol. 2011, 7:473-484.
19. Daka A., Peer D. RNAi-based nanomedicines for targeted personalized therapy. Adv. Drug Deliv. Rev. 2012, 64:1508-1521.
20. Dalby B., et al. Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applications. Methods 2004, 33:95-103.
21. Donnelly R.F., Raj Singh T.R., Woolfson A.D. Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety. Drug Deliv. 2010, 17:187-207.
22. Dou S., et al. Anti-Her2 single-chain antibody mediated DNMTs-siRNA delivery for targeted breast cancer therapy. J. Control. Release 2012, 161:875-883.
23. Drouet V., et al. Sustained effects of nonallele-specific Huntingtin silencing. Ann. Neurol. 2009, 65:276-285.
24. Dworakowski R., Anilkumar N., Zhang M., Shah A.M. Redox signalling involving NADPH oxidase-derived reactive oxygen species. Biochem. Soc. Trans. 2006, 34:960-964.
25. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
26. Erdal C., Emre Åžefik.a, Ali Demir S. Gene Delivery Systems: Recent Progress in Viral and Non-viral Therapy 2012.
27. Fakih M. The evolving role of VEGF-targeted therapies in the treatment of metastatic colorectal cancer. Expert. Rev. Anticancer. Ther. 2013, 13:427-438.
28. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
29. Frank-Kamenetsky M., et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:11915-11920.
30. Fu G.F., et al. RNA interference remarkably suppresses bcl-2 gene expression in cancer cells in vitro and in vivo. Cancer Biol. Ther. 2005, 4:822-829.
31. Fukuhara T., et al. Expression of microRNA miR-122 facilitates an efficient replication in nonhepatic cells upon infection with hepatitis C virus. J. Virol. 2012, 86:7918-7933.
32. Gao X., Huang L. A novel cationic liposome reagent for efficient transfection of mammalian cells. Biochem. Biophys. Res. Commun. 1991, 179:280-285.
33. Gavrilov K., Saltzman W.M. Therapeutic siRNA: principles, challenges, and strategies. Yale J. Biol. Med. 2012, 85:187-200.
34. Golovanova E.V. Treatment of chronic viral hepatitis: achievements and prospects. Eksp. Klin. Gastroenterol. 2012, 3-12.
35. Gonzalez-Gonzalez E., et al. Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device (PAD). Mol. Ther. 2010, 18:1667-1674.
36. Goodchild J. Therapeutic oligonucleotides. Methods Mol. Biol. 2011, 764:1-15.
37. Guo P., et al. Engineering RNA for targeted siRNA delivery and medical application. Adv. Drug Deliv. Rev. 2010, 62:650-666.
38. Hall A.H., Wan J., Shaughnessy E.E., Ramsay Shaw B., Alexander K.A. RNA interference using boranophosphate siRNAs: structure-activity relationships. Nucleic Acids Res. 2004, 32:5991-6000.
39. Hamilton A.J., Baulcombe D.C. A species of small antisense RNA in posttranscriptional gene silencing in plants. Science 1999, 286:950-952.
40. Harper S.Q., et al. RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5820-5825.
41. Hickerson R.P., et al. Stability study of unmodified siRNA and relevance to clinical use. Oligonucleotides 2008, 18:345-354.
42. Hong C.S., Goins W.F., Goss J.R., Burton E.A., Glorioso J.C. Herpes simplex virus RNAi and neprilysin gene transfer vectors reduce accumulation of Alzheimer's disease-related amyloid-beta peptide in vivo. Gene Ther. 2006, 13:1068-1079.
43. Hornung V., et al. Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7. Nat. Med. 2005, 11:263-270.
44. Huang P.I., Lo W.L., Cherng J.Y., Chien Y., Chiou G.Y., Chiou S.H. Non-viral delivery of RNA interference targeting cancer cells in cancer gene therapy. Curr. Gene Ther. 2012, 12:275-284.
45. Huang B., et al. Downregulation of the GnT-V gene inhibits metastasis and invasion of BGC823 gastric cancer cells. Oncol. Rep. 2013, 29:2392-2400.
46. Hu-Lieskovan S., Heidel J.D., Bartlett D.W., Davis M.E., Triche T.J. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res. 2005, 65:8984-8992.
47. Hussain A.F., Tur M.K., Barth S. An aptamer-siRNA chimera silences the eukaryotic elongation factor 2 gene and induces apoptosis in cancers expressing alphavbeta3 integrin. Nucleic Acid Ther. 2013, 23(3):203-212.
48. Hutvagner G., Simard M.J. Argonaute proteins: key players in RNA silencing. Nat. Rev. Mol. Cell Biol. 2008, 9:22-32.
49. Infanger D.W., Sharma R.V., Davisson R.L. NADPH oxidases of the brain: distribution, regulation, and function. Antioxid. Redox Signal. 2006, 8:1583-1596.
50. Ishida M., Selaru F.M. miRNA-Based therapeutic strategies. Curr. Anesthesiol. Rep. 2013, 1:63-70.
51. Jackson A.L., et al. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. Rna 2006, 12:1197-1205.
52. Jackson A.L., et al. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity. RNA 2006, 12:1179-1187.
53. Jacque J.M., Triques K., Stevenson M. Modulation of HIV-1 replication by RNA interference. Nature 2002, 418:435-438.
54. John B., Enright A.J., Aravin A., Tuschl T., Sander C., Marks D.S. Human microRNA targets. PLoS Biol. 2004, 2:e363.
55. Kataoka K., Harada A., Nagasaki Y. Block copolymer micelles for drug delivery: design, characterization and biological significance. Adv. Drug Deliv. Rev. 2001, 47:113-131.
56. Kawasaki A.M., et al. Uniformly modified 2'-deoxy-2'-fluoro phosphorothioate oligonucleotides as nuclease-resistant antisense compounds with high affinity and specificity for RNA targets. J. Med. Chem. 1993, 36:831-841.
57. Kesharwani P., Gajbhiye V., Jain N.K. A review of nanocarriers for the delivery of small interfering RNA. Biomaterials 2012, 33:7138-7150.
58. Kim Y.C., Park J.H., Prausnitz M.R. Microneedles for drug and vaccine delivery. Adv. Drug Deliv. Rev. 2012, 64:1547-1568.
59. Kronke J., et al. Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs. J. Virol. 2004, 78:3436-3446.
60. Landen C.N., et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res. 2005, 65:6910-6918.
61. Lara M.F., et al. Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays. Hum. Gene Ther. 2012, 23:816-823.
62. Leachman S.A., et al. First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol. Ther. 2009, 18:442-446.
63. Lee R.J., Low P.S. Delivery of liposomes into cultured KB cells via folate receptor-mediated endocytosis. J. Biol. Chem. 1994, 269:3198-3204.
64. Lee N.S., et al. Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells. Nat. Biotechnol. 2002, 20:500-505.
65. Li J., Loh X.J. Cyclodextrin-based supramolecular architectures: syntheses, structures, and applications for drug and gene delivery. Adv. Drug Deliv. Rev. 2008, 60:1000-1017.
66. Li H., Yang B.B. Friend or foe: the role of microRNA in chemotherapy resistance. Acta Pharmacol. Sin. 2013, 34(7):870-879.
67. Liang X.J., Chen C., Zhao Y., Wang P.C. Circumventing tumor resistance to chemotherapy by nanotechnology. Methods Mol. Biol. 2010, 596:467-488.
68. Liu J., et al. Argonaute2 is the catalytic engine of mammalian RNAi. Science 2004, 305:1437-1441.
69. Liu D., Hu J., Qiao W., Li Z., Zhan S., Cheng L. Synthesis and characterization of a series of carbamate-linked cationic lipids for gene delivery. Lipids 2005, 40:839-848.
70. Liu D., Hu J., Qiao W., Li Z., Zhang S., Cheng L. Synthesis of carbamate-linked lipids for gene delivery. Bioorg. Med. Chem. Lett. 2005, 15:3147-3150.
71. Liu J., et al. Functionalized dendrimer-based delivery of angiotensin type 1 receptor siRNA for preserving cardiac function following infarction. Biomaterials 2013, 34:3729-3736.
72. Lorenz C., Hadwiger P., John M., Vornlocher H.P., Unverzagt C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg. Med. Chem. Lett. 2004, 14:4975-4977.
73. Lu P., Yuan L., Wang Y., Du Q., Sheng J. Effect of GPE-AGT nanoparticle shRNA transfection system mediated RNAi on early atherosclerotic lesion. Int. J. Clin. Exp. Pathol. 2012, 5:698-706.
74. Malmo J., Sandvig A., Varum K.M., Strand S.P. Nanoparticle mediated P-glycoprotein silencing for improved drug delivery across the blood-brain barrier: a siRNA-chitosan approach. PLoS One 2013, 8:e54182.
75. Manoharan M. RNA interference and chemically modified small interfering RNAs. Curr. Opin. Chem. Biol. 2004, 8:570-579.
76. Martinez J., Patkaniowska A., Urlaub H., Luhrmann R., Tuschl T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002, 110:563-574.
77. Martinez M.A., et al. Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS 2002, 16:2385-2390.
78. Matokanovic M., Barisic K., Filipovic-Grcic J., Maysinger D. Hsp70 silencing with siRNA in nanocarriers enhances cancer cell death induced by the inhibitor of Hsp90. Eur. J. Pharm. Sci. 2013, 50(1):149-158.
79. McLeod H.L. Cancer pharmacogenomics: early promise, but concerted effort needed. Science 2013, 339:1563-1566.
80. Medarova Z., Pham W., Farrar C., Petkova V., Moore A. In vivo imaging of siRNA delivery and silencing in tumors. Nat. Med. 2007, 13:372-377.
81. Miele E., et al. Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int. J. Nanomedicine 2012, 7:3637-3657.
82. Motavaf M., Safari S., Alavian S.M. Therapeutic potential of RNA interference: a new molecular approach to antiviral treatment for hepatitis C. J. Viral Hepat. 2012, 19:757-765.
83. Niu Z., et al. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer. Acta Biochim. Biophys. Sin. (Shanghai) 2012, 44:991-998.
84. Novina C.D., et al. siRNA-directed inhibition of HIV-1 infection. Nat. Med. 2002, 8:681-686.
85. Parrish S., Fleenor J., Xu S., Mello C., Fire A. Functional anatomy of a dsRNA trigger: differential requirement for the two trigger strands in RNA interference. Mol. Cell 2000, 6:1077-1087.
86. Pawelek J.M., Chakraborty A.K. The cancer cell-leukocyte fusion theory of metastasis. Adv. Cancer Res. 2008, 101:397-444.
87. Peixoto A.J., Orias M., Desir G.V. Does kidney disease cause hypertension?. Curr. Hypertens. Rep. 2013, 15:89-94.
88. Peng K.A., Masliah E. Lentivirus-expressed siRNA vectors against Alzheimer disease. Methods Mol. Biol. 2010, 614:215-224.
89. Pieken W.A., Olsen D.B., Benseler F., Aurup H., Eckstein F. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science 1991, 253:314-317.
90. Ramachandran P.V., Ignacimuthu S. RNA interference as a plausible anticancer therapeutic tool. Asian Pac. J. Cancer Prev. 2012, 13:2445-2452.
91. Robb G.B., Brown K.M., Khurana J., Rana T.M. Specific and potent RNAi in the nucleus of human cells. Nat. Struct. Mol. Biol. 2005, 12:133-137.
92. Robbins M., Judge A., Liang L., McClintock K., Yaworski E., MacLachlan I. 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol. Ther. 2007, 15:1663-1669.
93. Rodriguez-Lebron E., Denovan-Wright E.M., Nash K., Lewin A.S., Mandel R.J. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol. Ther. 2005, 12:618-633.
94. Rose J.K., Buonocore L., Whitt M.A. A new cationic liposome reagent mediating nearly quantitative transfection of animal cells. Biotechniques 1991, 10:520-525.
95. Salta E., De Strooper B. Non-coding RNAs with essential roles in neurodegenerative disorders. Lancet Neurol. 2012, 11:189-200.
96. San H., et al. Safety and short-term toxicity of a novel cationic lipid formulation for human gene therapy. Hum. Gene Ther. 1993, 4:781-788.
97. Sapru M.K., Yates J.W., Hogan S., Jiang L., Halter J., Bohn M.C. Silencing of human alpha-synuclein in vitro and in rat brain using lentiviral-mediated RNAi. Exp. Neurol. 2006, 198:382-390.
98. Schiffelers R.M., et al. Transporting silence: design of carriers for siRNA to angiogenic endothelium. J. Control. Release 2005, 109:5-14.
99. Shi Y., et al. VEGF-C ShRNA inhibits pancreatic cancer growth and lymphangiogenesis in an orthotopic fluorescent nude mouse model. Anticancer Res. 2013, 33:409-417.
100. Siolas D., et al. Synthetic shRNAs as potent RNAi triggers. Nat. Biotechnol. 2005, 23:227-231.
101. Song J.J., Smith S.K., Hannon G.J., Joshua-Tor L. Crystal structure of Argonaute and its implications for RISC slicer activity. Science 2004, 305:1434-1437.
102. Song E., et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat. Biotechnol. 2005, 23:709-717.
103. Soutschek J., et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432:173-178.
104. Spelios M., Nedd S., Matsunaga N., Savva M. Effect of spacer attachment sites and pH-sensitive headgroup expansion on cationic lipid-mediated gene delivery of three novel myristoyl derivatives. Biophys. Chem. 2007, 129:137-147.
105. Stessl M., Marchetti-Deschmann M., Winkler J., Lachmann B., Allmaier G., Noe C.R. A proteomic study reveals unspecific apoptosis induction and reduction of glycolytic enzymes by the phosphorothioate antisense oligonucleotide oblimersen in human melanoma cells. J. Proteomics 2009, 72:1019-1030.
106. Strehlow K., Wassmann S., Bohm M., Nickenig G. Angiotensin AT1 receptor over-expression in hypercholesterolaemia. Ann. Med. 2000, 32:386-389.
107. Suva M.L., Riggi N., Bernstein B.E. Epigenetic reprogramming in cancer. Science 2013, 339:1567-1570.
108. Takeshita F., et al. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:12177-12182.
109. Tang T., et al. MicroRNA-182 plays an onco-miRNA role in cervical cancer. Gynecol. Oncol. 2013, 129:199-208.
110. Tomek M., Akiyama T., Dass C.R. Role of Bcl-2 in tumour cell survival and implications for pharmacotherapy. J. Pharm. Pharmacol. 2012, 64:1695-1702.
111. Ui-Tei K., et al. Functional dissection of siRNA sequence by systematic DNA substitution: modified siRNA with a DNA seed arm is a powerful tool for mammalian gene silencing with significantly reduced off-target effect. Nucleic Acids Res. 2008, 36:2136-2151.
112. Usui M., Egashira K. Angiotensin II receptor and oxidative stress. Nihon Rinsho 2002, 60:1893-1897.
113. Vlassov A.V., et al. shRNAs targeting hepatitis C: effects of sequence and structural features, and comparison with siRNA. Oligonucleotides 2007, 17:223-236.
114. Walker L.C., Diamond M.I., Duff K.E., Hyman B.T. Mechanisms of protein seeding in neurodegenerative diseases. JAMA Neurol. 2012, 70:304-310.
115. Wang Z., Rao D.D., Senzer N., Nemunaitis J. RNA interference and cancer therapy. Pharm. Res. 2011, 28:2983-2995.
116. Whitehead K.A., et al. Synergistic silencing: combinations of lipid-like materials for efficacious siRNA delivery. Mol. Ther. 2011, 19:1688-1694.
117. Wilner S.E., et al. An RNA alternative to human transferrin: a new tool for targeting human cells. Mol. Ther. Nucleic Acids 2012, 1:e21.
118. Wu Z., et al. In vitro and in vivo inhibition of MRP gene expression and reversal of multidrug resistance by siRNA. Basic Clin. Pharmacol. Toxicol. 2011, 108:177-184.
119. Xia H., Jun J., Wen-Ping L., Yi-Feng P., Xiao-Ling C. Chitosan nanoparticle carrying small interfering RNA to platelet-derived growth factor B mRNA inhibits proliferation of smooth muscle cells in rabbit injured arteries. Vascular 2013, 21:301-306.
120. Xie F.Y., Woodle M.C., Lu P.Y. Harnessing in vivo siRNA delivery for drug discovery and therapeutic development. Drug Discov. Today 2006, 11:67-73.
121. Xue B., Beltz T.G., Johnson R.F., Guo F., Hay M., Johnson A.K. PVN adenovirus-siRNA injections silencing either NOX2 or NOX4 attenuate aldosterone/NaCl-induced hypertension in mice. Am. J. Physiol. Heart Circ. Physiol. 2012, 302:H733-H741.
122. Yan C., Wang C., Dong M., Liu S., Qi C., Zhao Y. RNA interference-mediated silencing of VEGF and bFGF suppresses endostatin secretion in pancreatic carcinoma cells. Oncol. Lett. 2013, 5:1031-1035.
123. Yang J., Li S., Guo F., Zhang W., Wang Y., Pan Y. Induction of apoptosis by chitosan/HPV16 E7 siRNA complexes in cervical cancer cells. Mol. Med. Rep. 2012, 7:998-1002.
124. Yu J.Y., DeRuiter S.L., Turner D.L. RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:6047-6052.
125. Yu B., Zhao X., Lee L.J., Lee R.J. Targeted delivery systems for oligonucleotide therapeutics. AAPS J. 2009, 11:195-203.
126. Zamore P.D., Tuschl T., Sharp P.A., Bartel D.P. RNAi: double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000, 101:25-33.
127. Zhang Q., Li F. Combating P-glycoprotein-mediated multidrug resistance using therapeutic nanoparticles. Curr. Pharm. Des. 2013, 19(37):6655-6666.
128. Zhang B., Mallapragada S. The mechanism of selective transfection mediated by pentablock copolymers; part II: nuclear entry and endosomal escape. Acta Biomater. 2011, 7:1580-1587.
129. Zhang S., Zhao Y., Zhi D., Zhang S. Non-viral vectors for the mediation of RNAi. Bioorg. Chem. 2012, 40:10-18.
130. Zhang S., Zhi D., Huang L. Lipid-based vectors for siRNA delivery. J. Drug Target. 2012, 20:724-735.